New York, NY -- (SBWIRE) -- 01/02/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Solta Medical Inc (NASDAQ:SLTM), New Residential Investment Corp (NYSE:NRZ), BioScrip Inc (NASDAQ:BIOS), Oclaro, Inc (NASDAQ:OCLR)
Solta Medical Inc (NASDAQ:SLTM) showed a volume of 1.10 million shares by the end of last trade whereas the average volume of the stock remained 1.78 million shares. The stock opened the session at $2.98but then moved to $2.95. At that price, the stock showed a negative performance of -1.34%. Solta Medical, Inc. designs, develops, manufactures and markets professional and consumer energy-based medical device systems for aesthetic applications. The Company's systems are cleared by the United States Food and Drug Administration (FDA) for dermatological procedures performed in the physician led, professional assist, and personal care markets.
Will SLTM Get Buyers Even After The Recent Rally? Find Out Here
New Residential Investment Corp (NYSE:NRZ) opened the session at $6.68 and closed the session at $6.68. The stock showed a positive performance of 0.45% in previous trading session. New Residential Investment Corp., incorporated on September 26, 2013, is a real estate investment trust. The Company focuses on investing in, and actively managing, investments related to residential real estate. The Company is managed by an affiliate of Fortress Investment Group LLC, a global investment management.
For How Long NRZ will fight for Profitability? Read This Trend Analysis report
BioScrip Inc (NASDAQ:BIOS) opened the session at $7.28 and closed the session at $7.40. The stock showed a positive performance of 1.79% in previous trading session. The beta of the stock remained 1.43. BioScrip, Inc. (BioScrip) is a provider of pharmacy and home health services, which partners with patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and the delivery of prescription medications and home health services. Its platform provides service capabilities and the ability to deliver clinical management services,
Why Should Investors Buy BIOS After The Recent Gain? Just Go Here and Find Out
Oclaro, Inc (NASDAQ:OCLR) the stock advanced 1.22% and finished the session at $2.49. Traded with volume of 1.07 million shares in the prior session and the average volume of the stock remained 1.02 million shares. The beta of the stock remained 3.84. Oclaro, Inc. is a provider of optical communications and laser components, modules and subsystems for a range of markets, including telecommunications (telecom), industrial, scientific, consumer electronics and medical. The Company’s product offerings include tunable laser, lithium niobate external modulators, pump laser chips, thin film filters, and amplifiers. The Company is a supplier of optical network technology to telecom equipment companies worldwide.
Will OCLR Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)